Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptau1831ec

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 7	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 8	JAN 29	PHAR reloaded with new search and display fields
NEWS 9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13	FEB 26	MEDLINE reloaded with enhancements
NEWS 14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS 15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19	MAR 16	CASREACT coverage extended
NEWS 20	MAR 20	MARPAT now updated daily
NEWS 21	MAR 22	LWPI reloaded
NEWS 22	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 23	MAR 30	INPADOCDB will replace INPADOC on STN
NEWS 24	APR 02	JICST-EPLUS removed from database clusters and STN

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:17:20 ON 29 APR 2007

Copy for Scannings

```
=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 16:17:47 ON 29 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   27 APR 2007  HIGHEST RN 933069-51-3
DICTIONARY FILE UPDATES:  27 APR 2007  HIGHEST RN 933069-51-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10.521193.R1.Fishman.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 16:18:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       37 TO ITERATE

100.0% PROCESSED       37 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          376 TO     1104
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 16:18:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      622 TO ITERATE

100.0% PROCESSED      622 ITERATIONS                              35 ANSWERS
SEARCH TIME: 00.00.01
```

L3 35 SEA SSS FUL L1

=> d scan

L3 35 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Adenosine, 2-chloro-N-[(2,6-dihydroxy-3,5-diiodophenyl)methyl]- (9CI)
MF C17 H16 Cl I2 N5 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L3 35 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN β-D-Ribofuranuronamide, 1-[6-[[(2-chloro-3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl- (9CI)
MF C18 H18 Cl I N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 35 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Adenosine, N-[2-(4-amino-3-iodophenyl)ethyl]- (9CI)
MF C18 H21 I N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 35 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Adenosine, 3'-C-methyl-N-[(3-iodophenyl)methyl]- (9CI)
MF C18 H20 I N5 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> file caplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     173.00     173.21

FILE 'CAPLUS' ENTERED AT 16:19:27 ON 29 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 29 Apr 2007  VOL 146 ISS 19
FILE LAST UPDATED: 27 Apr 2007  (20070427/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d his

     (FILE 'HOME' ENTERED AT 16:17:20 ON 29 APR 2007)

     FILE 'REGISTRY' ENTERED AT 16:17:47 ON 29 APR 2007
L1             STRUCTURE UPLOADED
L2               0 S L1 SSS SAM
L3              35 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 16:19:27 ON 29 APR 2007

=> s l3
L4          312 L3

=> s l4 and multiple sclerosis
          425932 MULTIPLE
           27103 SCLEROSIS
           16693 MULTIPLE SCLEROSIS
                 (MULTIPLE(W)SCLEROSIS)
L5              5 L4 AND MULTIPLE SCLEROSIS

=> d l5 ed ibib abs hitstr 1-5

L5   ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2007 ACS on STN
ED   Entered STN:  15 Jul 2005
ACCESSION NUMBER:         2005:612088  CAPLUS
DOCUMENT NUMBER:          143:109816
TITLE:                    Method for treatment of multiple
                          sclerosis
INVENTOR(S):              Fishman, Pnina; Bar Yehuda, Sara; Madi, Lea
PATENT ASSIGNEE(S):       Can-Fite Biopharma Ltd., Israel
SOURCE:                   PCT Int. Appl., 23 pp.
                          CODEN: PIXXD2
```

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063246	A1	20050714	WO 2004-IL1160	20041223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1699459	A1	20060913	EP 2004-806691	20041223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1901915	A	20070124	CN 2004-80039334	20041223
US 2006142237	A1	20060629	US 2005-521193	20050113

PRIORITY APPLN. INFO.: US 2003-532712P P 20031229
WO 2004-IL1160 W 20041223

OTHER SOURCE(S): MARPAT 143:109816

AB Use of an A3 adenosine receptor agonist in the preparation of a pharmaceutical composition for the treatment of an individual suffering from multiple sclerosis. The composition is preferably orally administered. Also disclosed is a pharmaceutical composition for the treatment of multiple sclerosis that comprises an effective amount of an A3 adenosine receptor agonist and a pharmaceutically acceptable carrier.

IT 89705-21-5 152918-18-8, IB-MECA 152918-27-9, AB-MECA 163042-96-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for treatment of multiple sclerosis)

RN 89705-21-5 CAPLUS
CN Adenosine, N-[2-(4-aminophenyl)ethyl]- (9CI) . (CA INDEX NAME)

Absolute stereochemistry.



RN 152918-18-8 CAPLUS

CN β-D-Ribofuranuronamide, 1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 152918-27-9 CAPLUS
CN β-D-Ribofuranuronamide, 1-[6-[[(4-amino-3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163042-96-4 CAPLUS
CN β-D-Ribofuranuronamide, 1-[2-chloro-6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 15 Jul 2004
ACCESSION NUMBER: 2004:566634 CAPLUS
DOCUMENT NUMBER: 141:123865
TITLE: Substitution derivatives of N6-benzyl-adenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds
INVENTOR(S): Dolezal, Karel; Popa, Igor; Zatloukal, Marek; Lenobel, Rene; Hradecka, Dana; Vojtesek, Borivoj; Uldrijan, Stjepan; Mlejnek, Petr; Werbrouck, Stefaan; Strnad, Miroslav
PATENT ASSIGNEE(S): Ustav Experimentalni Botaniky Akademie Ved Ceske Republiky, Czech Rep.; et al.
SOURCE: PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058791	A2	20040715	WO 2003-CZ78	20031229
WO 2004058791	A3	20041028		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CZ 294538	B6	20050112	CZ 2002-4273	20021230
AU 2003294608	A1	20040722	AU 2003-294608	20031229
EP 1575973	A2	20050921	EP 2003-785482	20031229
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

US 2006166925 A1 20060727 US 2005-540993 20050815

PRIORITY APPLN. INFO.: CZ 2002-4273 A 20021230

WO 2003-CZ78 W 20031229

OTHER SOURCE(S): MARPAT 141:123865

GI



I

AB The invention concerns novel substitution derivs. of N6-benzyl-adenosine I, wherein n is 2-6; R1 is H, OH, halogen, alkoxy, amino, hydrazo, mercapto, methylmercapto, carboxyl, cyano, nitro, amido, sulfo, sulfamido, acylamino, acyloxy, alkylamino, dialkylamino, alkylmercapto, carbylalkoxy, cycloalkyl, carbamoyl alkyl; R2 is H, OH, halogen, alkoxy, amino, hydrazo, mercapto, methylmercapto, carboxyl, cyano, nitro, amido, sulfo, sulfamido, acylamino, acyloxy, alkylamino, dialkylamino, alkylmercapto, cabylalkoxy, cycloalkyl, carbamoyl, having anticancer, mitotic, immunosuppressive and anti-senescent properties for plant, animal and human cells. This invention also relates to the methods of preparation of these N6-benzyl-adenosine derivs. and their use as drugs, cosmetic prepns. and growth regulators comprising these derivs. as active compound and use of these derivs. for preparation of pharmaceutical compns., in biotechnol. processes, in cosmetics and in agriculture. Use of title compds. as mitotic or antimitotic compound, especially for treating cancer, psoriasis, rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis, restenosis, polycystic kidney disease, graft rejection, graft vs. host disease and gout, parasitoses such as those caused by fungi or protists, or Alzheimer's disease, or as anti-neurogenerative drugs, or to suppress immunostimulation or for the treatment of proliferative skin diseases. Thus, 2-amino-6-(2-methoxybenzylamino)purine riboside was prepared as growth regulator, and antitumor agent.

IT 163152-30-5P 163152-31-6P 722506-34-5P
722506-36-7P 722506-58-3P 722506-62-9P
722506-74-3P 722522-41-0P 722522-76-1P
722526-05-8P 722526-80-9P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); COS (Cosmetic use); IMF (Industrial manufacture); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N6-benzyladenosine nucleosides as antitumor, mitotic, immunosuppressive prodrugs, cosmetic agents, and growth regulators)

RN 163152-30-5 CAPLUS

CN Adenosine, N-[(3-iodophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163152-31-6 CAPLUS
CN Adenosine, 2-chloro-N-[(3-iodophenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 722506-34-5 CAPLUS
CN Adenosine, N-[(2-hydroxy-3-iodophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722506-36-7 CAPLUS
CN Adenosine, N-[(2-hydroxy-5-iodophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722506-58-3 CAPLUS
CN Adenosine, N-[(2,6-dihydroxy-3-iodophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722506-62-9 CAPLUS
CN Adenosine, N-[(2,6-dihydroxy-3,5-diiodophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722506-74-3 CAPLUS
CN Adenosine, N-[(3,4-diiodophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722522-41-0 CAPLUS
CN Adenosine, 2-chloro-N-[(2-hydroxy-3-iodophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722522-76-1 CAPLUS
CN Adenosine, 2-chloro-N-[(2-hydroxy-5-iodophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722526-05-8 CAPLUS
CN Adenosine, 2-chloro-N-[(2,6-dihydroxy-3-iodophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722526-80-9 CAPLUS
CN Adenosine, 2-chloro-N-[(2,6-dihydroxy-3,5-diiodophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 17 Oct 2001
ACCESSION NUMBER: 2001:757814 CAPLUS
DOCUMENT NUMBER: 135:298819
TITLE: Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors, and their therapeutic use
INVENTOR(S): Linden, Joel M.
PATENT ASSIGNEE(S): University of Virginia, USA; University of Virginia Patent Foundation
SOURCE: U.S., 16 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6303619	B1	20011016	US 1998-38991	19980312

PRIORITY APPLN. INFO.: US 1998-38991 19980312
OTHER SOURCE(S): MARPAT 135:298819

AB The invention concerns the use of a xanthine or xanthine derivative having a meta-substituted acidic aryl at the 8-position to specifically modulate the physiol. role of adenosine activation of its various receptors.

IT 98866-49-0 105834-00-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(xanthine aryl derivative antagonists of adenosine A3 receptor, and therapeutic use)

RN 98866-49-0 CAPLUS
CN Adenosine, N-[(4-amino-3-iodophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 105834-00-2 CAPLUS
CN Adenosine, N-[2-(4-amino-3-iodophenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 31 Aug 1999
ACCESSION NUMBER: 1999:549143 CAPLUS
DOCUMENT NUMBER: 131:165336
TITLE: Xanthine derivative antagonists of A2b human adenosine receptors, and therapeutic use thereof
INVENTOR(S): Linden, Joel M.
PATENT ASSIGNEE(S): University of Virginia, USA
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 9942093	A2	19990826	WO 1999-US4009		19990224
WO 9942093	A3	19991028			
W: AU, CA, JP, US					
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
US 6117878	A	20000912	US 1998-27649		19980224
AU 9928759	A	19990906	AU 1999-28759		19990224
PRIORITY APPLN. INFO.:			US 1998-27649	A	19980224
			WO 1999-US4009	W	19990224

AB 8-Phenylxanthines, 8-cycloalkylxanthines or 8-substituted xanthine derivs. are used to specifically modulate the physiol. role of the A2B adenosine receptor. A compound of the invention is e.g. enprofylline. The compds. of the invention are useful for e.g. blockage of inflammatory response and prevention of mast cell degranulation and can be used for the treatment of e.g. myocardial ischemia, asthma, or reperfusion injury.

IT 152918-18-8, IB-MECA
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(xanthine derivative antagonists of A2b human adenosine receptors, and therapeutic use)

RN 152918-18-8 CAPLUS

CN β-D-Ribofuranuronamide, 1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ED Entered STN: 29 Jul 1995

ACCESSION NUMBER:	1995:708692 CAPLUS
DOCUMENT NUMBER:	123:208767
TITLE:	Human adenosine receptor antagonists
INVENTOR(S):	Doyle, Michael P.; Jacobson, Marlene A.; Duling, Brian R.; Johnson, Robert G.; Linden, Joel M.
PATENT ASSIGNEE(S):	Merck and Co., Inc., USA; University of Virginia Patents Foundation
SOURCE:	PCT Int. Appl., 108 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 9511681	A1	19950504	WO 1994-US12272	19941026

W: CA, JP, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRIORITY APPLN. INFO.: US 1993-145437 A 19931029
OTHER SOURCE(S): MARPAT 123:208767

AB Compds. are identified through the use of recombinant human adenosine receptors A1, A2a, A2b, and A3, which specifically modulate the physiol. role of adenosine activation of its various receptors. In particular, a method is describing for achieving specific blockage of the A3 subtype of the adenosine receptor, and xanthines and xanthine derivs are described which display potent and specific A3-subtype specificity. Thus, full-length cDNAs were isolated and sequenced encoding the A1, A2a, A2b, and A3 receptors; these cDNAs were used in constructs for cloning expression in COS, CHO, and HEK 293 cells. The human A3 adenosine receptor cDNA encodes for a protein of 318 amino acids and exhibits 72 and 85% overall identity with the rat and sheep A3 adenosine receptor sequences, resp. Specific and saturable binding of the receptor agonist 125I-N6-aminobenzyladenosine was measured on the human A3 receptor stably expressed in CHO cells with a KD of 10 nM. The potency order or adenosine receptor agonists was determined to be N-ethylcarboxamidoadenosine ≥ R-phenylisopropyladenosine > N6-cyclopentyladenosine > S-phenylisopropyladenosine. The human receptor was blocked by xanthine antagonists; a partial listing of the pharmacol. is that the potency order of antagonists is I-ABOPX > 1,3-dipropyl-8-(4-acrylate) phenylxanthine (BW-A1433) ≥ xanthine amino congener (XAC) >> 1,3-dipropyl-8-0cyclopentylxanthine. Antagonist potencies determined by Schild analyses correlated well with those established by competition for radioligand binding. The tissue distribution of transcripts for all of the human adenosine receptor subtypes was compared. Compds. identified as antagonists are useful in preventing mast cell degranulation and are therefore useful in the treatment or prevention of disease states induced by activation of the A3 receptor and mast cell activation. These disease states include asthma, myocardial reperfusion injury, and allergic reactions including rhinitis, poison ivy-induced responses, urticaria, scleroderma, arthritis, other autoimmune diseases, and inflammatory bowel diseases.

IT 89705-21-5 98866-49-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human adenosine receptor antagonists)

RN 89705-21-5 CAPLUS
CN Adenosine, N-[2-(4-aminophenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 98866-49-0 CAPLUS
CN Adenosine, N-[(4-amino-3-iodophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 16:17:20 ON 29 APR 2007)

FILE 'REGISTRY' ENTERED AT 16:17:47 ON 29 APR 2007
L1 STRUCTURE UPLOADED
L2 0 S L1 SSS SAM
L3 35 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 16:19:27 ON 29 APR 2007
L4 312 S L3
L5 5 S L4 AND MULTIPLE SCLEROSIS

=> d his

(FILE 'HOME' ENTERED AT 16:17:20 ON 29 APR 2007)

FILE 'REGISTRY' ENTERED AT 16:17:47 ON 29 APR 2007

```
L1              STRUCTURE UPLOADED
L2            0 S L1 SSS SAM
L3           35 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 16:19:27 ON 29 APR 2007
L4          312 S L3
L5            5 S L4 AND MULTIPLE SCLEROSIS

=> d his

     (FILE 'HOME' ENTERED AT 16:17:20 ON 29 APR 2007)

     FILE 'REGISTRY' ENTERED AT 16:17:47 ON 29 APR 2007
L1              STRUCTURE UPLOADED
L2            0 S L1 SSS SAM
L3           35 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 16:19:27 ON 29 APR 2007
L4          312 S L3
L5            5 S L4 AND MULTIPLE SCLEROSIS
```